Ontology highlight
ABSTRACT:
SUBMITTER: El-Amm J
PROVIDER: S-EPMC4445785 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
El-Amm Joelle J Aragon-Ching Jeanny B JB
OncoTargets and therapy 20150518
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a novel first-in-class alpha-emitting radiopharmaceutical that has been approved for treatment of patients ...[more]